venetoclax monotherapy for relapsed/refractory multiple myeloma
Published 7 years ago • 221 plays • Length 2:46Download video MP4
Download video MP3
Similar videos
-
5:49
magnetismm-3 extended follow up results: elranatamab monotherapy in r/r multiple myeloma
-
2:40
venetoclax and ruxolitinib treatment strategies for myeloma
-
1:28
clinical management of venetoclax in multiple myeloma
-
2:03
the use of venetoclax in r/r al amyloidosis
-
1:47
venetoclax and the future of treatment of multiple myeloma
-
1:31
maic of pirtobrutinib vs venetoclax continuous monotherapy in patients with r/r cll
-
1:47
cilta-cel in earlier lines of therapy for r/r multiple myeloma
-
5:52
the power of venetoclax
-
3:28
the sympatico trial: ibrutinib plus venetoclax in tp53-mutated mcl
-
3:48
the current treatment landscape in multiple myeloma
-
2:10
venetoclax in r/r mm patients
-
3:03
outcomes following venetoclax monotherapy in patients with r/r wm in the real-world setting
-
2:33
patient-specific targeted therapy in myeloma: t(11;14) and venetoclax
-
0:50
the expanding therapeutic landscape of r/r multiple myeloma
-
1:41
innovative treatment strategies for multiple myeloma
-
1:49
venetoclax as a potential treatment for mm with t(11;14)
-
1:54
can venetoclax be used to treat multiple myeloma (mm)?
-
1:30
a phase i trial of voruciclib /- venetoclax for the treatment of nhl and aml
-
4:30
next steps for myeloma research and treatment
-
1:17
novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
-
1:43
e7820 in combination with venetoclax in patients with splicing factor mutant myeloid malignancies